REDUCING INFLUENZA BURDEN IN OLDER ALGERIANS: COST-EFFECTIVENESS ANALYSIS OF HIGH DOSE VS STANDARD DOSE INACTIVATED INFLUENZA VACCINE IN ADULTS AGED 75 AND OLDER
Author(s)
Merzak Gharnaout, Professor of Pneumology1, Reda Djidjik, PhD, MD2, Gerald Moncayo, PhD3, zakia hachelaf, MBA, MSc4.
1Youssef Al-Khatib University of Health Sciences, Algiers, Algeria, algiers, Algeria, 2Faculty of pharmacy, Youssef Al-Khatib University of Health Sciences, Algiers, Algeria, Alger, Algeria, 3sanofi, Lyon, France, 4market access manager, Sanofi, algiers, Algeria.
1Youssef Al-Khatib University of Health Sciences, Algiers, Algeria, algiers, Algeria, 2Faculty of pharmacy, Youssef Al-Khatib University of Health Sciences, Algiers, Algeria, Alger, Algeria, 3sanofi, Lyon, France, 4market access manager, Sanofi, algiers, Algeria.
OBJECTIVES: In Algeria, seasonal influenza poses a significant clinical and economic burden, particularly among older adults who are at high risk of life-threatening complications due to immunosenescence. High-dose inactivated influenza vaccine (HD-IIV) was developed to address this protection gap. However, cost-effectiveness studies comparing HD-IIV and standard-dose inactivated influenza vaccine (SD-IIV) are not available for Algeria. This study evaluated the health outcomes and cost-effectiveness of HD-IIV versus SD-IIV for adults aged 75+ in Algeria.
METHODS: A static decision-tree model was developed to analyze healthcare outcomes (influenza cases, general practitioner [GP] visits, emergency room [ER] visits and cardiorespiratory hospitalizations) and associated costs for each vaccination strategy over one influenza season. Key model inputs included relative vaccine efficacy (32.4%; FIM12 trial) for influenza cases and relative vaccine effectiveness of 16.7% against cardiorespiratory hospitalizations from meta-analysis. Deterministic and probabilistic sensitivity analyses explored variations in parameters. Incremental cost-effectiveness ratios (ICERs) were assessed from an Algerian healthcare payer perspective.
RESULTS: In the base case analysis, implementing HD-IIV instead of SD-IIV averted 2026 influenza cases, 363 GP visits, and 344 ER visits. HD-IIV also averted 619 cardiorespiratory hospitalizations. HD-IIV demonstrated savings in terms of influenza-associated GP visit costs (1,247,139 DZD), reduced ER visit costs (94,757,139 DZD), and cardiorespiratory hospitalization costs (183,163,532 DZD). The ICER was (1,118,410 DZD) per life-year gained and (1,154,226 DZD) per quality-adjusted life-year (QALY) gained, equivalent to €7905 per QALY, which is below the threshold of 1-3 times GDP per capita recommended by WHO. Sensitivity analyses confirmed robustness, with results most sensitive to hospitalization rates and influenza season adjustment factors.
CONCLUSIONS: HD-IIV was shown to be cost-effective versus SD-IIV in older adults aged 75+ in Algeria, potentially reducing the burden on healthcare systems. These findings provide evidence to support age-adapted influenza vaccination strategies within Algeria's national immunization program.
METHODS: A static decision-tree model was developed to analyze healthcare outcomes (influenza cases, general practitioner [GP] visits, emergency room [ER] visits and cardiorespiratory hospitalizations) and associated costs for each vaccination strategy over one influenza season. Key model inputs included relative vaccine efficacy (32.4%; FIM12 trial) for influenza cases and relative vaccine effectiveness of 16.7% against cardiorespiratory hospitalizations from meta-analysis. Deterministic and probabilistic sensitivity analyses explored variations in parameters. Incremental cost-effectiveness ratios (ICERs) were assessed from an Algerian healthcare payer perspective.
RESULTS: In the base case analysis, implementing HD-IIV instead of SD-IIV averted 2026 influenza cases, 363 GP visits, and 344 ER visits. HD-IIV also averted 619 cardiorespiratory hospitalizations. HD-IIV demonstrated savings in terms of influenza-associated GP visit costs (1,247,139 DZD), reduced ER visit costs (94,757,139 DZD), and cardiorespiratory hospitalization costs (183,163,532 DZD). The ICER was (1,118,410 DZD) per life-year gained and (1,154,226 DZD) per quality-adjusted life-year (QALY) gained, equivalent to €7905 per QALY, which is below the threshold of 1-3 times GDP per capita recommended by WHO. Sensitivity analyses confirmed robustness, with results most sensitive to hospitalization rates and influenza season adjustment factors.
CONCLUSIONS: HD-IIV was shown to be cost-effective versus SD-IIV in older adults aged 75+ in Algeria, potentially reducing the burden on healthcare systems. These findings provide evidence to support age-adapted influenza vaccination strategies within Algeria's national immunization program.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE293
Topic
Economic Evaluation, Epidemiology & Public Health
Disease
Infectious Disease (non-vaccine), Vaccines